Serotonergic Therapies for Cognitive Symptoms in Alzheimer's Disease: Rationale and Current Status

Overview

Journal Drugs

Specialty Pharmacology

Date 2014 May 8

PMID 24802806

Citations 30

Authors

Maria J Ramirez

Mitchell K P Lai

Rosa M Tordera

Paul T Francis

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in elderly people. Research focused on identifying compounds that restore cognition and memory in AD patients is a very active investigational pursuit. Cholinesterase inhibitors for the symptomatic treatment of cognitive decline in AD have been in use for more than a decade but provide only modest benefits in most patients. Preclinical research is constantly providing new information on AD. The involvement of the serotonergic system in higher cognitive processes such as memory and learning has been widely described and extensive serotonergic denervation has been reported in AD. This review aims to explain the rationale behind testing serotonergic therapies for AD in terms of current knowledge about the pathophysiology of the disease. Based on preclinical studies, certain serotonin (5-HT) receptor ligands have been suggested to have the ability to modify or improve memory/cognition, specifically 5-HT receptors acting at 5-HT1A, 5-HT4 and 5-HT6 receptors. This article summarizes the pharmacology, efficacy, safety and tolerability data for the various serotonergic agents currently in clinical development for AD.

Citing Articles

Shattering the Amyloid Illusion: The Microbial Enigma of Alzheimer's Disease Pathogenesis-From Gut Microbiota and Viruses to Brain Biofilms.

Onisiforou A, Charalambous E, Zanos P Microorganisms. 2025; 13(1).

PMID: 39858858 PMC: 11767882. DOI: 10.3390/microorganisms13010090.

Drugs repurposing in the experimental models of Alzheimer's disease.

Joodi S, Ibrahim W, Khattab M Inflammopharmacology. 2025; 33(1):195-214.

PMID: 39752040 PMC: 11799062. DOI: 10.1007/s10787-024-01608-7.

Serotonin enhances neurogenesis biomarkers, hippocampal volumes, and cognitive functions in Alzheimer's disease.

Azargoonjahromi A Mol Brain. 2024; 17(1):93.

PMID: 39696587 PMC: 11654273. DOI: 10.1186/s13041-024-01169-4.

Exploring the most promising anti - Depressant drug targeting Microtubule Affinity Receptor Kinase 4 involved in Alzheimer's Disease through molecular docking and molecular dynamics simulation.

Ahmad S, Zeyaullah M, AlShahrani A, Khan M, Muzammil K, Ahmed F PLoS One. 2024; 19(7):e0301179.

PMID: 39052643 PMC: 11271900. DOI: 10.1371/journal.pone.0301179.

Dorsal raphe nucleus-hippocampus serotonergic circuit underlies the depressive and cognitive impairments in 5×FAD male mice.

Chen M, Wang C, Lin Y, Chen Y, Xie W, Huang X Transl Neurodegener. 2024; 13(1):34.

PMID: 39044270 PMC: 11267773. DOI: 10.1186/s40035-024-00425-w.

References

Schechter L, Smith D, Rosenzweig-Lipson S, Sukoff S, Dawson L, Marquis K . Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther. 2005; 314(3):1274-89. DOI: 10.1124/jpet.105.086363. View

Finkel S, Mintzer J, Dysken M, Krishnan K, Burt T, McRae T . A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004; 19(1):9-18. DOI: 10.1002/gps.998. View

Chen C, Eastwood S, Hope T, McDonald B, Francis P, Esiri M . Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol. 2000; 26(4):347-55. DOI: 10.1046/j.1365-2990.2000.00254.x. View

Dayan P, Huys Q . Serotonin in affective control. Annu Rev Neurosci. 2009; 32:95-126. DOI: 10.1146/annurev.neuro.051508.135607. View

Javier Ramirez M . 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2):15. PMC: 3706851. DOI: 10.1186/alzrt169. View

Lai M, Tsang S, Esiri M, Francis P, Wong P, Chen C . Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease. Psychopharmacology (Berl). 2010; 213(2-3):431-9. DOI: 10.1007/s00213-010-1936-2. View

Dawson L, Nguyen H, Li P . The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001; 25(5):662-8. DOI: 10.1016/S0893-133X(01)00265-2. View

Sawant-Basak A, Coffman K, Walker G, Ryder T, Tseng E, Miller E . Metabolism of a serotonin-4 receptor partial agonist 4-{4-[4-tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (TBPT): identification of an unusual pharmacologically active cyclized oxazolidine.... J Pharm Sci. 2013; 102(9):3277-93. DOI: 10.1002/jps.23542. View

Staubli U, Xu F . Effects of 5-HT3 receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat. J Neurosci. 1995; 15(3 Pt 2):2445-52. PMC: 6578162. View

10.

Patat A, Parks V, Raje S, Plotka A, Chassard D, Le Coz F . Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Br J Clin Pharmacol. 2009; 67(3):299-308. PMC: 2675040. DOI: 10.1111/j.1365-2125.2008.03348.x. View

11.

Robert S, Zugaza J, Fischmeister R, Gardier A, Lezoualch F . The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J Biol Chem. 2001; 276(48):44881-8. DOI: 10.1074/jbc.M109008200. View

12.

Meneses A, Liy-Salmeron G . Serotonin and emotion, learning and memory. Rev Neurosci. 2012; 23(5-6):543-53. DOI: 10.1515/revneuro-2012-0060. View

13.

Francis P, Pangalos M, Stephens P, Bartlett J, Bridges P, Malizia A . Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression. J Neurol Neurosurg Psychiatry. 1993; 56(1):80-4. PMC: 1014771. DOI: 10.1136/jnnp.56.1.80. View

14.

Kepe V, Barrio J, Huang S, Ercoli L, Siddarth P, Shoghi-Jadid K . Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2006; 103(3):702-7. PMC: 1334681. DOI: 10.1073/pnas.0510237103. View

15.

Mowla A, Mosavinasab M, Pani A . Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. 2007; 27(1):67-70. DOI: 10.1097/JCP.0b013e31802e0002. View

16.

Mohler E, Shacham S, Noiman S, Lezoualch F, Robert S, Gastineau M . VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology. 2007; 53(4):563-73. DOI: 10.1016/j.neuropharm.2007.06.016. View

17.

Millan M, Marin P, Bockaert J, Mannoury la Cour C . Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci. 2008; 29(9):454-64. DOI: 10.1016/j.tips.2008.06.007. View

18.

Hodges M, Richerson G . The role of medullary serotonin (5-HT) neurons in respiratory control: contributions to eupneic ventilation, CO2 chemoreception, and thermoregulation. J Appl Physiol (1985). 2010; 108(5):1425-32. PMC: 2867541. DOI: 10.1152/japplphysiol.01270.2009. View

19.

Mowla A, Mosavinasab M, Haghshenas H, Haghighi A . Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2007; 27(5):484-7. DOI: 10.1097/jcp.0b013e31814b98c1. View

20.

Lai M, Tsang S, Francis P, Esiri M, Keene J, Hope T . Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003; 974(1-2):82-7. DOI: 10.1016/s0006-8993(03)02554-x. View